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PCSK9 (proprotein convertase subtilisin/kexin type 9) promotes
degradation of the LDLR [LDL (low-density lipoprotein)
receptor] through an as-yet-undeﬁned mechanism, leading to a
reduction in cellular LDLc (LDL-cholesterol) and a concomitant
increase in serum LDLc. Central to the function of PCSK9 is
a direct protein–protein interaction formed with the LDLR. In
the present study, we investigated a strategy to modulate LDL
uptake by blocking this interaction using speciﬁc antibodies
directedagainstPCSK9.Studiesusingsurfaceplasmonresonance
demonstrated that direct binding of PCSK9 to the LDLR could
be abolished with three different anti-PCSK9 antibodies. Two
of these antibodies were raised against peptide epitopes in a
region of the catalytic domain of PCSK9 that is involved in
the interaction with the LDLR. Such antibodies restored LDL
uptake in HepG2 cells treated with exogenous PCSK9 and in
HepG2cellsengineeredtooverexpressrecombinantPCSK9.This
latter observation indicates that antibodies blocking the PCSK9–
LDLR interaction can inhibit the action of PCSK9 produced
endogenously in a cell-based system. These antibodies also
disrupted the higher-afﬁnity interaction between the natural gain-
of-function mutant of PCSK9, D374Y, and the LDLR in both the
cell-freeandcell-basedassays.Thesedataindicatethatantibodies
targeting PCSK9 can reverse the PCSK9-mediated modulation of
cell-surface LDLRs.
Key words: antibody-mediated disruption, cholesterol, low-den-
sity lipoprotein receptor, proprotein convertase subtilisin/kexin
type 9 (PCSK9), protein–protein interaction, surface plasmon
resonance.
INTRODUCTION
Cardiovascular disease is one of the great plagues of our afﬂuent
society, responsible for approx. 30% of all deaths each year. In
addition to lifestyle risk factors, such as poor diet and smok-
ing, genetic predisposition also contributes to the prevalence of
the disease. Sufferers of familial hypercholesterolaemia exhibit
highly elevated serum LDLc [LDL (low-density lipoprotein)-
cholesterol] levels, leading to premature atherosclerosis [1].
Recently, a novel serine protease, PCSK9 (proprotein convertase
subtilisin/kexin type 9) was identiﬁed as the third genetic locus
for autosomal dominant hypercholesterolaemia [2]. PCSK9 is
involved in the metabolism of LDLc through its action on the
LDLR (LDL receptor), degrading the receptor via a mechanism
which has yet to be fully elucidated [3,4].
Structurally, PCSK9 consists of a 30 aa (amino acid) signal
peptide, followed by a prodomain (aa 31–152), a catalytic
domain(aa153–425)andaCHRD(C-terminalcysteine/histidine-
rich domain) (aa 426–692) [3]. PCSK9 is synthesized as a
∼72 kDa precursor protein that undergoes autocatalytic cleavage
in the endoplasmic reticulum [5]. After cleavage, the ∼14 kDa
prodomain remains tightly associated with the active site,
rendering the mature protein catalytically inactive [6,7]. PCSK9
undergoes a variety of post-translational modiﬁcations before
being secreted efﬁciently from the cell [5,8].
In cell-culture systems, overexpression of PCSK9 resulted in
a decrease in LDLR levels via a post-transcriptional mechanism
[9]. However, PCSK9 does not affect the synthesis or trafﬁcking
of the LDLR [10]. The addition of media containing recombinant
PCSK9toHepG2cellscausedareductioninthenumberofsurface
LDLRs [11–13]. It has now been established that PCSK9 forms
a direct protein–protein interaction with the EGF-A (epidermal
growth factor-like repeat A) domain of the LDLR that results
in targeting of the LDLR to lysosomes for degradation [14,15].
This interaction appears to be necessary, and may be sufﬁcient,
for PCSK9-mediated LDLR degradation, a hypothesis supported
by two studies showing that the addition of catalytically inactive
PCSK9 to HepG2 cells decreased LDLR levels to the same extent
as wild-type PCSK9 [16,17]. Further evidence supporting the
importance of the PCSK9–LDLR interaction was the discovery
that the natural PCSK9 gain-of-function mutant D374Y, which
causes a particularly severe form of hypercholesterolaemia, has a
signiﬁcantly increased binding afﬁnity for the LDLR [6,13].
In the present study, we investigated a strategy to disrupt
the interaction between PCSK9 and the LDLR using speciﬁc
antibodies directed against PCSK9, and examined the effects this
has on LDL uptake in cellular models.
EXPERIMENTAL
cDNA and site-directed mutagenesis
The cDNA encoding human PCSK9 (GenBank® accession num-
ber AX207686) was ampliﬁed by PCR using gene-speciﬁc pri-
mers and incorporating a 3
  FLAG tag sequence (DYKDDDDK)
to aid puriﬁcation of the expressed product, and attB1 and attB2
sites at the 5
  and 3
  ends respectively. The resulting PCR pro-
duct was inserted into the Gateway® donor vector pDONR221
(Invitrogen) using the BP clonase reaction (Invitrogen) and
Abbreviations used: aa, amino acids; BODIPY®, boron dipyrromethene (4,4-diﬂuoro-4-bora-3a,4a-diaza-s-indacene; CHRD, cysteine/histidine-rich
domain; EGF-A, epidermal growth factor-like repeat A; FBS, fetal bovine serum; HEK-F cells, FreestyleTM suspension human embryonic kidney cells;
IL1Ra, interleukin-1 receptor antagonist; LDL, low-density lipoprotein; LDLc, LDL-cholesterol; LDLR, LDL receptor; MOI, multiplicity of infection; PCSK9,
proprotein convertase subtilisin/kexin type 9; RU, resonance units; SPR, surface plasmon resonance.
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subsequently transferred to the Gateway® destination vector,
pFastBacMam-2-rfa (a variant of the plasmid described in
[18], containing additional polylinker sequences), via the LR
clonase reaction (Invitrogen). To generate the PCSK9 mutants,
site-directedmutagenesiswascarriedoutonpDONR221-PCSK9-
FLAG using the QuikChange® II XL kit (Stratagene). For the
D374Ymutant,themutagenicprimers5
 -CATTGGTGCCTCCA-
GCTATTGCAGCACCTGCTTTG-3
  (forward) and 3
 -GTAA-
CCACGGAGGTCGATAACGTCGTGGACGAAAC-5
  (reverse)
were used. For the RRRR
218EL mutant, the mutagenic primers
5
 -GGACGGGACCCGCCGCCGCAGAGAGCTAAGCAAGT-
GTGAC-3
  (forward) and 5
 -GTCACACTTGCTTAGCTCTC-
TGCGGCGGCGGGTCCCGTCC-3
  (reverse) were used. The
residues in bold indicate the site of mutation.
Antibodies
The afﬁnity-puriﬁed anti-PCSK9 polyclonal antibody AF3888,
raised against mature (aa 31–692) PCSK9, was from R&D
Systems. The afﬁnity-puriﬁed goat anti-PCSK9 polyclonal
antibody (Ab28770), raised against peptide aa 679–692, was
from Abcam. The anti-PCSK9 polyclonal antibodies, E6675
and E6660, were raised in rabbits against the peptides GEDII-
GASSDCSTCFVSQSG (aa 365–384) and NVPEEDGTRFH-
RQASKC (aa 207–223) respectively and were afﬁnity-puriﬁed
using the respective peptides. A non-speciﬁc control polyclonal
antibody [rabbit anti-IL1Ra (interleukin-1 receptor antagonist)]
was from Abcam.
Cell culture
Spodoptera frugiperda (Sf9) cells (Invitrogen) were cultured in
ExCell 420 insect cell medium (JRH Biosciences) at 27◦C with
shaking at 125 rev./min. Cell densities were maintained between
0.3×10
6 and 5×10
6 cells/ml. HEK-F (Freestyle
TM suspension
human embryonic kidney) cells (Invitrogen) were cultured in
Freestyle
TM 293 serum-free medium (Gibco, Invitrogen) at 37◦C
under 5% CO2 with shaking at 125 rev./min. HEK-F cells were
routinely passaged to maintain a cell density between 0.5×10
6
and 3×10
6 cells/ml. HepG2 cells were cultured in advanced
minimum essential medium (Gibco) containing 110 mg/l sodium
pyruvate and non-essential amino acids, supplemented with
2m M L-glutamine, 10% (v/v) FBS (fetal bovine serum) and
100 units/ml penicillin/streptomycin (all Gibco) at 37◦C under
5% CO2. The cells were routinely passaged with 50% (v/v)
TrypLE
TM Express in Versene (Gibco).
BacMam virus generation and transduction of mammalian
cell lines
BacMam viruses were generated using standard procedures for
the Bac-to-Bac system (Invitrogen) as described previously
[18,19]. For transduction to enable protein puriﬁcation, the HEK-
F cells were cultured to a density of 2.5×10
6 cells/ml and to
this, the BacMam virus inoculum at 10
8 pfu (plaque-forming
units)/ml was added at 20% (v/v) to give a ﬁnal cell density
of 2×10
6 cells/ml and an MOI (multiplicity of infection) of 10.
The transduced culture was then incubated for 3 days at 37◦C
under 5% CO2 with shaking at 125 rev./min. For transduction to
enable functional studies, the HepG2 cells were seeded in a 96-
well tissue-culture plate at 30000 cells/well, and after 24 h, the
medium was removed and replaced with 50 μl of recombinant
BacMam virus inoculum, giving a MOI of ∼80. The cells were
incubated with the virus for 1 h at 37◦C before replacing the
inoculum with normal growth medium.
PCSK9 puriﬁcation
The HEK-F cell culture medium from a 1 litre BacMam
transduction of either wild-type PCSK9 or mutant D374Y was
passed through a 0.22 μm pore size ﬁlter and mixed with 10 ml
ofanti-FLAGM2–agaroseafﬁnitychromatographyresin(Sigma)
overnight at 4 ◦C with rotation. The resin was collected in a 50 ml
Econocolumn (Bio-Rad Laboratories) and washed twice with at
least 10 column vol. of ice-cold PBS. The FLAG-tagged protein
was eluted from the column using triple FLAG peptide (Sigma)
diluted to 100 μg/ml in PBS. Peak fractions, determined by A280,
were pooled and concentrated to a volume of 2.5 ml (approx.
5 mg/ml)usinganAmiconUltra-15(30 kDacut-off)concentrator
(Millipore) before being loaded on to a HiLoad 16/60 Superdex
200size-exclusioncolumn(GEHealthcare)forseparationinPBS
at a ﬂow rate of 1 ml/min (¨ AKTA Explorer, GE Healthcare). Peak
fractionswerepooledandstoredat−80◦C.Toassesspurity,5 μg
of the pooled protein was analysed on a NuPAGE Novex 4–12%
acrylamide Bis-Tris gel (Invitrogen) under reducing conditions.
Resolved proteins were visualized with GelCode Blue Stain
Reagent (Pierce).
SPR (surface plasmon resonance)
Using the amine-coupling kit (Biacore) and the Biacore T100
immobilization wizard, puriﬁed LDLR ectodomain (His-tagged,
R&D Systems) was immobilized to one of the four ﬂow cells of a
CM5 sensorchip to a level of approx. 150 RU (resonance units).
Puriﬁed wild-type PCSK9 or the D374Y mutant were diluted in
10 mM Hepes (pH 7.4), 150 mM NaCl and 0.1 mM CaCl2 to a
range of concentrations and passed over the sensorchip surface at
a ﬂow rate of 30 μl/min. Each cycle consisted of a 120 s analyte
injection (the association phase), followed by a 300 s dissoci-
ation phase. Regeneration was achieved using a 60 s injection of
10 mM glycine/HCl (pH 2.0) with a 300 s stabilization period.
The data were analysed using the Biacore T100 Evaluation
software. Baselines were adjusted to zero for all curves and
double-referenced by subtracting a sensorgram of buffer injected
over the LDLR surface from the experimental sensograms to
give curves representing speciﬁc binding. Curves were modelled
assuming a simple 1:1 interaction to generate the kinetic data.
For antibody-blocking experiments, the ectodomain of the
LDLR was amine-coupled to a CM5 sensorchip at an abundance
of 2000 RU. Wild-type PCSK9 was diluted to 50 nM in
Dulbecco’s PBS plus Ca
2+,M g
2+ and 0.005% Surfactant P20,
and pre-incubated for 1 h at 4◦C with each antibody at 500 nM.
The samples were then subject to SPR binding analysis using
parameters identical with those described above. The Biacore
T100 Evaluation software was used to calculate the maximum
binding level achieved in the presence of each antibody.
BODIPY® [boron dipyrromethene (4,4-diﬂuoro-4-bora-3a,4a-diaza-
s-indacene)]–LDL uptake assay
HepG2 cells cultured in normal growth medium were seeded
at 30000 cells/well in black walled 96-well tissue-culture plates.
After24 h,themediumwasreplacedwithnormalgrowthmedium
containing 1% FBS. After a further 18 h, the medium was
replaced again, this time with normal growth medium lacking
FBS, but containing 10 μg/ml BODIPY®–LDL (Invitrogen) as
well as variousconcentrations(0–20 μg/ml) of puriﬁedwild-type
PCSK9 or D374Y (1 μg/ml PCSK9=13.9 nM). The cells were
then incubated for 6 h at 37◦C. After two washes with PBS, the
ﬂuorescencewasmeasuredat485 nmexcitation/535 nmemission
using a Tecan ULTRA ﬂuorescent plate reader. To assess cell
viability, the Cell Titre-Glo® cell viability assay kit (Promega)
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was used following the manufacturer’s instructions. Antibody-
blocking experiments were carried out with the same protocol,
this time using PCSK9 at 2.5 μg/ml and incorporating a pre-
incubation step at 4◦C for 1 h before cell treatment with various
concentrations (0–100 μg/ml) of antibody.
Alternatively, the cells were transduced 24 h after seeding with
recombinantBacMamvirusforwild-type,D374YorRRRR
218EL
PCSK9. Cells were cultured in normal growth medium for
42 h, before exchange for serum-free growth medium containing
10 μg/ml BODIPY®–LDL. Plates were then incubated at 37◦C
for 6 h and washed, and ﬂuorescence was measured as described
above. To conduct antibody-blocking experiments, the inoculum
was replaced, immediately after BacMam transduction, with
normal growth medium (+1% FBS) containing antibody at
various concentrations (0, 10, 25 or 50 μg/ml). After incubation
at 37◦C for 24 h, the medium was replaced with fresh antibody/
medium mixture at the same concentration. After a further 18 h,
the cells were replenished with antibody, this time in medium
lacking FBS, but containing 10 μg/ml BODIPY®–LDL. After a
further 6 h of incubation at 37◦C, the plates were washed with
PBS and the ﬂuorescence was measured as before.
RESULTS
Puriﬁcation and functional validation of PCSK9
Wild-type PCSK9 and the D374Y gain-of-function mutant were
expressed as C-terminal FLAG-tag-fusion proteins via BacMam-
mediated transduction of HEK-F cells. The secreted mature
form of PCSK9 was puriﬁed from the culture medium using
anti-FLAG afﬁnity chromatography followed by size-exclusion
chromatography. The puriﬁed wild-type and D374Y forms of
PCSK9 migrated with an apparent molecular mass of ∼60 kDa
on SDS/PAGE (Figure 1A). Also visible, at ∼16 kDa, was the
PCSK9prodomain,whichremainedtightlyassociatedthroughout
the puriﬁcation, but dissociated under the denaturing conditions
of SDS/PAGE. The identity of the preparation was conﬁrmed by
peptide mass ﬁngerprinting and N-terminal sequencing (results
not shown).
In order to functionally validate puriﬁed wild-type PCSK9
and the D374Y gain-of-function mutant, we characterized their
bindingtotheLDLRusingSPR.Thepuriﬁedextracellulardomain
oftheLDLRwasimmobilizedtothesurfaceofaCM5sensorchip
via amine-coupling. Puriﬁed wild-type PCSK9 was passed over
thesurfaceofthechipatarangeofconcentrations,andthebinding
kinetics of the interaction were determined from the resulting
sensograms (Figure 1B). By ﬁtting a 1:1 binding model to these
data,anafﬁnityconstant(Kd)of810 nMatpH 7.4wasdetermined
(Table 1), consistent with data published previously [7,13]. The
D374Y mutant displayed an approx. 25-fold greater afﬁnity for
the LDLR than the wild-type protein (Figure 1C and Table 1), in
agreement with previous reports [6,13]. The mean association
(kon) and dissociation (koff) constants for each interaction are
reported in Table 1. All χ
2 values were below 5 RU
2, indicating a
good ﬁt to the binding model.
Anti-PCSK9 antibodies block the PCSK9–LDLR interaction
A potential strategy for blocking protein–protein interactions is
to use an antibody directed against one of the binding partners. To
investigatethisapproach,avarietyofanti-PCSK9antibodieswere
assessed for their ability to block the PCSK9–LDLR interaction
in an SPR binding assay (Figure 2). Pre-incubation of PCSK9
with three afﬁnity-puriﬁed anti-PCSK9 antibodies resulted in
disruption of the interaction. These antibodies were AF3888
Figure 1 Binding afﬁnity of wild-type PCSK9 and the D374Y mutant for the
LDLR
(A) FLAG-tagged versions of wild-type (WT) PCSK9 and the D374Y mutant were puriﬁed as
describedintheExperimentalsection,and1μgofeachproteinwassubjectedtoelectrophoresis
on a 4–12% acrylamide NuPAGE Novex gel (Invitrogen) followed by staining with Coomassie
Blue. Molecular-mass markers (sizes in kDa) are indicated on the left. The puriﬁed extracellular
domainoftheLDLRwasimmobilizedonthesurfaceofaCM5sensorchip,andwild-typePCSK9
(B) and the D374Y mutant (C) at concentrations of 7000, 1750, 438, 109, 27, 7, 2 and 0nM
were passed over the surface as described in the Experimental section. The response from the
reference surface was subtracted, and the baselines adjusted to zero to give response over time
binding curves.
(a polyclonal antibody raised against mature PCSK9) and two
polyclonal antibodies, E6675 and E6660, raised against PCSK9
peptide sequences (Figure 2). At a concentration of 500 nM,
AF3888 reduced the binding of PCSK9 to the LDLR by 81%,
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Table 1 Binding afﬁnities for wild-type PCSK9 and the D374Y mutant with
the LDLR
Results are means+ −S.E.M. (n=4).
PCSK9 kon (×10−4 M−1 ·s−1) koff (×102 s−1) Kd(nM)
Wild-type 2.38 (+ −0.33) 1.92 (+ −0.41) 810
D374Y 12.8 (+ −2.09) 0.42 (+ −0.05) 33.0
Figure 2 Antibody interference of the PCSK9–LDLR interaction
LDLR was immobilized via amine coupling to a CM5 sensorchip. Wild-type PCSK9 at 50 nM
was pre-incubated for 1h at 4◦C with one of four anti-PCSK9 polyclonal antibodies (AF3888,
E6675, E6660 or Ab28770) or a non-speciﬁc control antibody (anti-IL1Ra) and passed over the
sensorchip surface as described in the Experimental section. (A) Representative sensorgram
showing the signiﬁcantly decreased binding level observed in the presence of 500nM antibody
AF3888. (B) Relative binding level observed in the presence of 500nM of the indicated
antibodies. Results are the means+ −S.E.M. for three independent experiments. *P <0.05
compared with no antibody.
whereas E6675 and E6660 reduced binding by 90 and 89%
respectively. A fourth anti-PCSK9 antibody, Ab28770, raised
against a C-terminal peptide did not block the binding of PCSK9
to the LDLR, but instead gave an apparent increased binding
level (Figure 2B). This effect may be due to the inability of
Ab28770 to prevent PCSK9 binding to the LDLR; the increased
signal corresponds to the increased mass of the PCSK9–Ab28770
complex relative to PCSK9 alone. No effect was seen with the
control antibody directed against IL1Ra (Figure 2B).
Inordertolocatethebindingsitesoftheanti-PCSK9antibodies,
the immunizing peptide sequences were mapped on to a PCSK9
Figure 3 Predicted epitopes of the antibodies on the surface of PCSK9
(A) The epitopes of the anti-peptide antibodies E6675 (orange) and E6660 (magenta) were
mappedontothesurfaceofthecrystalstructureofPCSK9(PDBcode2P4E).(B)Theepitopefor
Ab28770(red)andtheregionshowntointeractwiththeEGF-AdomainoftheLDLR(blue)mapped
on to the structure of PCSK9. The prodomain is shown in grey, the catalytic domain is shown
in green, the CHRD is shown in yellow, and the site of the gain-of-function mutation D374Y is
shown in black. Figure drawn using PyMOL (DeLano Scientiﬁc; http://pymol.sourceforge.net/).
crystal structure. Consistent with our observations, the epitopes
for the blocking antibodies E6675 (aa 365–384) and E6660 (aa
207–223) both map to a discrete area of the catalytic domain
surroundingAsp
374 (Figure3A),aregionwhichiscriticalinmedi-
ating the interaction with the LDLR EGF-A domain (Figure 3B)
[14,15]. The epitope for Ab28770 (aa 679–692) lies within the
CHRD, a region of PCSK9 that is not involved in binding to
t h eL D L R( F i g u r e3 B ) .
Blocking the PCSK9–LDLR interaction inhibits PCSK9 function and
restores cellular LDL uptake
In order to monitor PCSK9 function, cell-surface LDLR levels
wereassessedindirectlybymonitoringtheuptakeofﬂuorescently
labelled LDL by HepG2 cells. Cells were treated for 6 h with
various concentrations of puriﬁed recombinant PCSK9 (wild-
type or D374Y) in the presence of BODIPY®–LDL particles.
Therewasadose-dependentreductioninBODIPY®–LDLuptake
after treatment with puriﬁed PCSK9 (Figure 4A). The increased
bindingafﬁnityofthegain-of-functionmutantwasclearlyevident
in this system. Following treatment with wild-type PCSK9 at
a concentration of 1 μg/ml, there was a moderate decrease in
LDL uptake of 28%, whereas a concentration of 20 μg/ml was
required to get a near-maximal decrease in LDL uptake of 69%.
In contrast, a near-maximal decrease in LDL uptake of 69% was
obtained with D374Y at a concentration of 0.5 μg/ml.
To assess whether blocking the PCSK9–LDLR interaction can
prevent PCSK9-mediated LDLR degradation, LDL uptake was
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Figure 4 Blocking the extracellular PCSK9–LDLR interaction inhibits
PCSK9-mediated LDLR degradation and restores LDL uptake
(A)HepG2cellswereincubatedfor6hwithvariousconcentrationsofpuriﬁedPCSK9[wild-type
(WT) or D374Y] in the presence of BODIPY®–LDL, the cells were then washed twice with PBS,
andtheﬂuorescencewasmeasuredat485nmexcitation/535nmemission.Resultsarepresented
as a percentage of the LDL taken up by the cells in the absence of PCSK9. Puriﬁed wild-type
PCSK9 (B) or the D374Y mutant (C)a t2 . 5μg/ml (34.7nM) were pre-incubated for 1h with
increasing concentrations of antibody AF3888 or control antibodies IL1Ra and Ab28770 before
addition to the HepG2 cells and determination of their relative LDL uptake. Results are the
percentage reversal of the PCSK9 effect on LDL uptake, and are means+ −S.E.M. for three
independent experiments each performed in triplicate. *P <0.05.
monitored following pre-incubation of puriﬁed PCSK9 using
the blocking antibody AF3888, non-blocking antibody Ab28770
orcontrolanti-IL1Raantibody.Theblockingantibody,butnotthe
control antibodies, dose-dependently blocked the action of wild-
type PCSK9 on the LDLR, thereby restoring uptake of LDL to
normallevels(Figure4B).Anantibodyconcentrationof50 μg/ml
(20-fold molar excess) was sufﬁcient to give complete reversal of
the PCSK9 effect on LDL uptake. In addition, we demonstrated
that the action of the gain-of-function mutant, D374Y, could be
similarly disrupted, obtaining complete reversal of its effect on
LDL uptake with blocking antibody at 100 μg/ml (Figure 4C).
Thenon-blockingandcontrolantibodiesdidnotreversetheeffects
of either the wild-type or mutant PCSK9 on BODIPY®–LDL
uptake (Figures 4B and 4C).
Antibody-mediated inhibition of the effect of overexpressed PCSK9
in HepG2 cells
To assess further the function of the blocking antibody, a
novel PCSK9-overexpression cellular system was employed. The
relative amount of BODIPY®–LDL uptake was quantiﬁed after
BacMam-mediated PCSK9 overexpression in HepG2 cells. LDL
uptake by the cells was measured 48 h after treatment with
recombinantBacMamvirusexpressingwild-typePCSK9,D374Y
or RRRR
218EL. The latter construct has been mutated from
RFHR
218QA to give a site within PCSK9 that is optimized for
furincleavage.Thisconstructactsasacontrolforthisexperiment,
since it is completely processed by furin, resulting in a truncated
form of the protein (PCSK9- N218) that is secreted, but is no
longer sorted to endosomes and does not affect the levels of
LDLR [8]. Overexpression of wild-type PCSK9 reduced LDL
uptakeby38%,whereastheD374Ygain-of-functionmutantcon-
struct reduced it by 77% (Figure 5A). As expected, the control
construct, RRRR
218EL, had little effect on LDL uptake by the
HepG2 cells. All three constructs were expressed and secreted
into the medium at similar levels (Figure 5B), indicating that
the differences observed in LDL uptake between each construct
were not due to variation in expression. The RRRR
218EL mutant
appearedasabandofapprox.53 kDa,representingPCSK9- N218
(Figure 5B, lane 3), as described previously [8].
For antibody-inhibition studies, blocking or control antibodies
were incubated with the cells immediately after BacMam virus
transduction, replenishing with antibody after 24 and 42 h,
followed by quantiﬁcation of BODIPY®–LDL uptake after a sub-
sequent 6 h incubation period. Antibody AF3888 restored LDL
uptake in a dose-dependent manner by 31% at a concentration
of 50 μg/ml for wild-type PCSK9 (Figure 5C) and by 23% at a
concentration of 100 μg/ml for D374Y (Figure 5D). There was
no comparable increase in LDL uptake when cells were treated
in the same way with the control antibody against IL1Ra. The
viability of cells expressing wild-type PCSK9 or the D374Y
mutant was unaffected by the presence of AF3888 (Figures 5E
and 5F).
DISCUSSION
The present study represents the ﬁrst demonstration that the
interaction between PCSK9 and the LDLR can be successfully
disrupted using antibodies directed against PCSK9. Furthermore,
we have shown that blocking the interaction in this way reduces
PCSK9-mediated LDLR degradation in a hepatocyte cell-based
system. Three antibodies capable of mediating this effect were
identiﬁed: a commercial polyclonal antibody raised against full-
length PCSK9 (AF3888) and two polyclonal antibodies raised
against peptides corresponding to regions of PCSK9 known to be
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Figure 5 Antibody AF3888 counteracts the effect of PCSK9 expression on LDLR degradation in HepG2 cells
(A)HepG2cellsweretransducedwithrecombinantBacMamvirusconstructsencodingwild-type(WT)PCSK9,D374YorRRRR218ELasdescribedintheExperimentalsection.After42h,themedium
was changed and replaced with serum-free growth medium containing 10μg/ml BODIPY®–LDL. After 6h, the cells were washed twice with PBS and the ﬂuorescence was measured at 485nm
excitation/535nm emission. Results are presented as a percentage of the LDL taken up by untransduced cells and are representative of three independent experiments, each carried out in triplicate.
*P <0.05. (B) Western blot of secreted PCSK9 (wild-type, D374Y and RRRR218EL) in the medium of HepG2 cells after BacMam-mediated overexpression. PCSK9 was detected via its FLAG tag
using an anti-FLAG M2 peroxidase-conjugated antibody. For antibody-blocking experiments, immediately after transduction with either wild-type (WT) PCSK9 (C) or D374Y (D) BacMam virus,
the inoculum was replaced with normal growth medium containing various concentrations of antibody AF3888 or control antibody IL1Ra. After 24 h, the medium was replaced with fresh medium
containing antibody at the same concentration. After a further 16h, the medium/antibody mixture was replenished, this time with the addition of 10μg/ml BODIPY®–LDL. After 6 h, the cells were
washed twice with PBS and their relative ﬂuorescence was determined. Results are presented as percentage reversal of the PCSK9 effect on LDL uptake. Cell viability (determined using the Cell
Titre-Glo® kit from Promega) is presented as a percentage of control (BacMam-transduced, antibody-untreated cells) after antibody-blocking experiments for wild-type PCSK9 (E) and D374Y
(F) transductions. For (C–F), black bars indicate AF3888, and white bars indicate IL1Ra. Results are the means+ −S.E.M. for three independent experiments each performed in triplicate, except for
(D) which are the mean+ −S.E.M. for three independent experiments each performed in duplicate. *P <0.05.
crucial for LDLR binding [14,15]. A fourth anti-PCSK9 antibody
to an epitope in the CHRD that is not involved in the interaction
with the LDLR was used to demonstrate that antibody binding
alone was not sufﬁcient to disrupt the interaction.
In a cell-based functional assay monitoring uptake of ﬂuo-
rescently labelled LDL, pre-incubation of puriﬁed recombinant
PCSK9 with antibody AF3888 led to a reduction in PCSK9-
mediated LDLR degradation, allowing levels of cellular LDL
uptake to return to normal. In order to assess further the effect of
the antibody, the BODIPY®–LDL uptake assay was modiﬁed to
incorporate BacMam virus-mediated overexpression of PCSK9
in place of treatment with puriﬁed protein. When transduced cells
overexpressing PCSK9 (wild-type or the gain-of-function mutant
D374Y) were incubated with the blocking antibody, AF3888,
there was reversal of the PCSK9 effect on LDL uptake relative to
transducedcellsintheabsenceofblockingantibody.Additionally,
the results of the present study demonstrate that the higher-
afﬁnity interaction between the D374Y mutant and LDLR could
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also be disrupted, albeit with higher concentrations of antibody
than were required to disrupt the wild-type PCSK9–LDLR
interaction.
The antibody-mediated reversal of the PCSK9 effect on LDL
uptake was lower in the cell-based model when PCSK9 was over-
expressed in the cells rather than being added exogenously as a
puriﬁed protein. This may reﬂect that insufﬁcient antibody was
present to neutralize the continual overexpression of PCSK9.
However, we did seek to overcome this by replenishing the
medium during the time course of the experiment with the maxi-
mum amount of fresh antibody that the experimental system
would allow. An alternative possibility is that there may be an
additional cellular site of interaction between PCSK9 and LDLR
that is inaccessible to the antibody. Indeed, there is evidence
to suggest that PCSK9 may act upon the LDLR in a post-
endoplasmic reticulum compartment before its secretion [10,20],
in addition to the well-characterized effect of secreted PCSK9
on cell-surface LDLR. Nevertheless, our data clearly show that
antibodies blocking the PCSK9–LDLR interaction can inhibit the
action of PCSK9 endogenously produced in a cell-based system.
During the course of the present study, it was reported that the
isolated EGF-A domain of the LDLR was sufﬁcient to inhibit
the LDLR-lowering effect of puriﬁed PCSK9 added exogenously
to HEK-293 cells [21]. Epitope excision and MS using PCSK9
and the PCSK9–EGF-A complex revealed that aa 175–210 of
PCSK9 remained bound to EGF-A after protease treatment and
washing. Interestingly, this region overlaps with the peptide
(aa 207–223) against which antibody E6660 was raised and
which we have shown blocks the interaction of PCSK9 with the
LDLR.
Despite the success of currently available lipid-lowering
therapeutics, there are still >267 million people worldwide that
have a plasma total cholesterol concentration of >200 mg/dl
(5.17 mmol/l) [22], signiﬁcantly increasing their risk of coronary
heart disease, a condition that accounts for >30% of all
deaths in North America [22]. In addition to their inhibition
of cholesterol synthesis and the resultant up-regulation of the
LDLR, the most widely prescribed class of drugs, the statins,
also have the effect of up-regulating PCSK9 [23,24]. This
potentially limits their efﬁcacy, and suggests that supplementing
this therapy with an agent inhibiting the action of PCSK9 may
have signiﬁcant beneﬁt. This approach is supported by studies of
Pcsk9-knockoutmice,aswellashumanswithmissensemutations
in PCSK9, which both exhibit increased sensitivity to statins
[23,25]. Furthermore, reducing PCSK9 expression, either via
antisenseorRNAi(RNAinterference),effectivelyreducesplasma
LDLc levels in rodents and non-human primates [26,27]. An
alternativeapproachtopreventthebiologicaleffectofPCSK9isto
abrogatebindingofPCSK9totheLDLRusingantibodiesorsmall
molecules [28], rather than reducing expression of endogenous
PCSK9.
In summary, the present paper reports the ﬁrst demonstration
that antibodies directed against PCSK9 are able to speciﬁcally
block its interaction with the LDLR. In vitro, such antibodies
were able to inhibit the interaction between puriﬁed recombinant
PCSK9 and the extracellular domain of the LDLR. Those
antibodies capable of blocking the interaction mapped to the
region on PCSK9 were reported recently to interact directly with
the LDLR EGF-A domain [14,15]. We have demonstrated further
using cell-based LDL-uptake assays that one of these blocking
antibodies could inhibit the effect of both wild-type PCSK9 and
the D374Y natural gain-of-function mutant. The results suggest
that targeting PCSK9 using a speciﬁc antibody may represent a
strategy for the treatment of dyslipidaemia by reversing PCSK9-
mediated modulation of cell-surface LDLRs.
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